Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07150845 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Enrollment target: estimated 120 to confirmed 121
    • Primary completion date changed from estimate of Jul 2026 to Jul 23, 2026
    • Study completion date changed from estimate of Jul 2026 to Aug 3, 2026
    • Eligibility criteria expanded, about 8 words
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 29 of 29 sites
    v8
  3. Study sites: 25 to 29v7
  4. Study sites: 18 to 25v6
  5. Study sites: 12 to 18v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 11 to 12v4
  2. Study sites: 9 to 11v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 9 of 9 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Trial Details
NCT Number NCT07150845
Lead Sponsor Evommune, Inc.
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic, Eczema, Pruritus
Enrollment 121 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov